CD Diagnostics is a leader in joint fluid analysis and is focused on developing novel diagnostic tests for joint disease. Our goal is to improve patient outcomes by introducing new technology that provides a more accurate and rapid diagnosis for joint pain. As part of our commitment to joint fluid research, CD Diagnostics is creating a repository of joint fluid samples from a national physician network to facilitate biomarker screening services for synovial and spinal fluids. By combining biomarker identification with our patented technology and core strengths in immunoassay development and manufacturing, our company is able to produce a range of products that address the most challenging diagnostic determinations in joint health and therapeutic outcomes. CD Diagnostics continues to develop both Laboratory Developed Tests (LDTs) and Point-of-Care (POC) devices utilizing corporate partnerships with market leaders. We perform all LDT testing and test analysis services in our CLIA certified laboratory, which has delivered reliable patient results to clients for over 39 years.
Looking for a particular CD Diagnostics, Inc employee's phone or email?
CD Diagnostics, Inc Questions
The CD Diagnostics, Inc annual revenue was $7.4 million in 2026.
CD Diagnostics, Inc is based in Claymont, Delaware.
The NAICS codes for CD Diagnostics, Inc are [325, 32541, 3254, 32, 325413].
The SIC codes for CD Diagnostics, Inc are [283, 28].
